These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
944 related articles for article (PubMed ID: 17307586)
1. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. Mavrokokki T; Cheng A; Stein B; Goss A J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586 [TBL] [Abstract][Full Text] [Related]
2. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538 [TBL] [Abstract][Full Text] [Related]
3. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738 [TBL] [Abstract][Full Text] [Related]
4. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. Kunchur R; Need A; Hughes T; Goss A J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200 [TBL] [Abstract][Full Text] [Related]
5. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913 [TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788 [TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620 [TBL] [Abstract][Full Text] [Related]
8. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504 [TBL] [Abstract][Full Text] [Related]
9. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study. Carmagnola D; Celestino S; Abati S Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):e10-5. PubMed ID: 18801674 [TBL] [Abstract][Full Text] [Related]
10. [Bisphosphonates and osteonecrosis of the jaws]. Urade M Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882 [TBL] [Abstract][Full Text] [Related]
11. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series. Goss A; Bartold M; Sambrook P; Hawker P J Oral Maxillofac Surg; 2010 Feb; 68(2):337-43. PubMed ID: 20116705 [TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Marx RE; Sawatari Y; Fortin M; Broumand V J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172 [TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483 [TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443 [TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid. García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097 [TBL] [Abstract][Full Text] [Related]
16. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Brooks JK; Gilson AJ; Sindler AJ; Ashman SG; Schwartz KG; Nikitakis NG Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun; 103(6):780-6. PubMed ID: 17223592 [TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. Favia G; Pilolli GP; Maiorano E J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275 [TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259 [TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. King AE; Umland EM Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663 [TBL] [Abstract][Full Text] [Related]
20. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]